Harbour BioMed and Evinova have announced a strategic collaboration to integrate artificial intelligence (AI) and digital technologies into biologics research and development. The partnership aims to boost the efficiency of innovative drug discovery while establishing an open ecosystem for AI-driven R&D.
Under the agreement, Harbour BioMed and Evinova China will combine their respective expertise—Harbour BioMed’s strong antibody discovery platform and Evinova’s digital health and AI capabilities—to accelerate the development of new biotherapeutics in immunology and oncology.
“We are pleased to collaborate with Evinova to advance the application of AI in biotherapeutic development,” said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. “This collaboration will help improve clinical study efficiency and speed up the delivery of innovative therapies to patients worldwide.”
Nate Zhang, General Manager of Evinova China, added, “By partnering with companies like Harbour BioMed, we aim to leverage world-class AI technology and therapeutic expertise to bring China-originated breakthrough assets to the global stage.”
The collaboration marks a key step toward harnessing AI to transform the biologics R&D landscape and accelerate innovation in global healthcare.